文献速递慢性肾脏病遗传性与小管间质肾病

常染色体显性多囊肾病临床试验终点需求:PKDOC报告

Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
PubMed 文献 · Am J Kidney Dis · 2018-12-29

常染色体显性多囊肾病(ADPKD)是最常见的遗传性肾病,目前仅有一种获批疗法。2016年7月PKD Outcomes Consortium召集患者、监管者、药企和学术研究者召开峰会并后续电话会议,讨论ADPKD临床试验终点与监管审批路径,本文基于这些讨论阐述试验设计的关键考量。

要点

  • ADPKD是最常见遗传性肾病,囊肿扩张可致部分患者肾功能进行性丧失和肾衰竭。
  • 目前美国及其他地区仅有一种疗法获批用于ADPKD治疗。
  • 可行的终点和清晰监管路径可能促进ADPKD新药研发上市。

核心结论

  • 需要可行的临床试验终点和清晰的监管路径以促进ADPKD新疗法开发并成功上市。

研究设计与样本

  • 2016年7月由PKD Outcomes Consortium在Critical Path Institute和PKD Foundation支持下召开PKD峰会,会后通过定期电话会议继续讨论。

主要发现

  • 峰会汇集患者、监管者、制药申办方和学术临床试验研究者,共同讨论ADPKD试验终点与监管审批路径。
  • 本文基于上述讨论阐述ADPKD临床试验设计的关键考量。

临床怎么用

  • 临床 trial 设计ADPKD研究时可参考本文关于终点选择和监管路径的关键考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease. Expansion of multiple cysts throughout both kidneys is thought to lead to progressive loss of kidney function and kidney failure in some patients. In recent years, much has been learned about the pathophysiology of ADPKD. However, to date, only one therapy has been approved in the United States and in other regions for the treatment of ADPKD. Feasible end points and a clear regulatory pathway may stimulate further development in this area and ultimately lead to more treatments for ADPKD successfully reaching the market. In July 2016, the PKD Outcomes Consortium under the auspices of the Critical Path Institute and the PKD Foundation convened a PKD Summit to facilitate a discussion among patients, regulators, pharmaceutical sponsors, and academic clinical trialists regarding trial end points and the regulatory path to approval of new drugs for ADPKD. Following the summit, participants continued the dialogue using regularly scheduled teleconferences. This article addresses key considerations related to the design of clinical trials in ADPKD based on these discussions.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Smith KA, Thompson AM, Baron DA, et al. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2018. PMID: 30600104. doi:10.1053/j.ajkd.2018.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。